CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 34 enrolled
Drug / intervention
Yerba Mate Extract +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02789722
NCT02789722N/ACompleted

Application of Yerba Mate (Ilex Paraguariensis A.St.-Hil.) Products on the Promotion of Health: Assessment of Cardiovascular Health

Karimi Sater Gebara·interventional·Posted Jun 3, 2016·Updated May 8, 2018

In Brief

A clinical study evaluating Yerba Mate Extract and Placebo for Cardiovascular Disease and Diabetes. Completed, enrolled 34 participants across 1 site.

Detailed Summary

Mate or yerba-mate (Ilex paraguariensis A.St.-Hil.) is a native plant from South America highly consumed in this region. Different traditional products (mate, mate tea, chimarrao, tereré) are obtained from the yerba-mate leaves and consumed as herbal tea. Mate is a rich source of bioactive phenolic compounds, mainly caffeoylquinic acids. The richness of different mono- and dicaffeoylquinic acids is a peculiarity of mate derived products. However, in contrast to other plant-based beverages rich in polyphenols like tea or coffee, the research and the industry have yet little explored the potential interest of mate product to promote human health. There has been a growing interest to the development of healthier foods to face the burden of cardiovascular diseases (CVD), especially those naturally rich in bioactive phenolic compounds with protective effects against the development of chronic diseases. Different in vitro and animals studies associate the mate consumption with cardiovascular protection mechanisms. Consistent information about this activity and the long-term consumption effects in humans are scarce. The aim of this study is to assess through a randomized controlled trial the impact of chronic intake of mate on intermediate biomarkers of cardiovascular health in humans and to identify possible involved nutrigenomic mechanisms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBrazil

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJun 3, 2016
Enrollment StartAug 15, 2016
Primary CompletionJun 30, 2017
Study CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.1 years ago

Interventions

Yerba Mate Extractother

Yerba Mate extract capsules 750 mg

Placeboother

Take 3 capsules, 3 times daily for 28 days.